BA.2.12.1 poised to turn out to be dominant in US, elevating concern for future vaccines

A medical worker arranges nucleic acid samples at a makeshift nucleic acid testing site on May 3, 2022 in Beijing, China.

Enlarge / A medical employee arranges nucleic acid samples at a makeshift nucleic acid testing website on Might 3, 2022 in Beijing, China. (credit score: Getty | Pang Songgang)

The omicron subvariant BA.2.12.1 is poised to turn out to be dominant within the US, presently accounting for an estimated 36.5 p.c of all US SARS-CoV-2 circumstances, in response to the most recent estimates launched Tuesday by the Facilities for Illness Management and Prevention.

The subvariant’s ascent is the most recent speedy succession of omicron subvariants, from the sky-scraping peak of circumstances from the preliminary omicron subvariant BA.1 in January, to the present bump pushed by the subvariant BA.2, which achieved dominance in March. As earlier than, the rationale for the viral usurping is that omicron subvariants proceed to evolve benefits: BA.2.12.1 has a transmission benefit over BA.2, which had a transmission benefit over BA.1, which had a big benefit over delta.

The upcoming reign of BA.2.12.1 raises concern for one more wave of infections and poses questions on how efficient future omicron-specific vaccines may very well be in opposition to symptomatic infections.

Learn 9 remaining paragraphs | Feedback

Related Posts

Leave a Reply

Your email address will not be published.